Danaher CorporationNYSE: DHR

Danaher Corporation closed its $9.9 billion acquisition of Masimo Corporation on June 10, 2026, making Masimo a wholly-owned subsidiary operating within the Diagnostics segment under the Masimo brand. The deal brings pulse oximetry, advanced sensor technology, and AI-enabled patient monitoring capabilities to Danaher's portfolio. No material Masimo contribution is expected in Q2 2026; management will update full-year 2026 guidance when Q2 earnings are released. DHR closed at $180.51 on June 16, with analyst consensus at 22 Buy and 3 Hold ratings and an average price target of $244.27, implying significant upside. The primary risk is integration complexity and slower-than-expected life-science end-market recovery.

Danaher Completes Acquisition of Masimo Corporationprnewswire.comDanaher Completes Acquisition of Masimo Corporation - Jun 10, 2026investors.danaher.comDanaher jumps as investors focus on fresh financing steps and Masimo deal progressquiverquant.com

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

Danaher completed its acquisition of Masimo Corporation on June 10, 2026, bringing Masimo's advanced sensor technology, trusted brand, and AI-enabled patient monitoring into Danaher's diagnostics segment as a complementary capability. The deal expands Danaher's specialty diagnostics reach into pulse oximetry and patient monitoring. Separately, Piper Sandler initiated coverage with a Neutral rating and a $200 price target, calling Danaher the highest-quality compounder in life science tools and citing the Danaher Business System as a defensible advantage. The company's Biotechnology segment continues to show momentum with core revenues up about 7% year-over-year. The main risk is integration execution on a large acquisition amid an only-Neutral analyst stance near current levels.

Danaher Completes Acquisition of Masimo Corporationprnewswire.comPiper Sandler initiates Danaher stock coverage with neutral ratinginvesting.comDanaher News & Press Releasesdanaher.com

Danaher shares climbed 3.9% on May 19, 2026 driven by a rebound in sentiment after recent weakness, helped by fresh analyst commentary nudging price targets higher and maintaining bullish ratings. Masimo shareholders approved Danaher's $9.9 billion acquisition of the company on May 4, with the deal expected to close in the second half of 2026 subject to regulatory clearance. Danaher's board approved a quarterly cash dividend of $0.40 per share, payable July 31. The company raised EPS guidance to $8.35-$8.55 after a Q1 beat on adjusted EPS of $2.06 despite a revenue miss at $5.95 billion. Consensus rating remains Buy with median 12-month target of $240. Despite the bounce, DHR is still down about 28% YTD.

Danaher shares climb as analysts turn more constructive after Q1 guidance liftquiverquant.comKirkland Advises Danaher on $9.9 Billion Acquisition of Masimokirkland.com

Danaher's annual meeting on May 5, 2026 saw shareholders re-elect all eleven directors, ratify Ernst & Young as auditor, and approve executive pay packages. CEO Rainer Blair delivered an investor presentation at the BofA Securities Healthcare Conference on May 13, 2026 in Las Vegas. The company is progressing through financing and regulatory steps for the Masimo acquisition, including a EUR 3.0B notes issuance. The stock has remained under pressure recently with analyst downgrades and concerns over top-line growth despite Q1 EPS beating at $2.06. Management has guided to 3-6% growth in 2026 driven by bioprocessing recovery and diagnostics stabilization. Average analyst rating remains Strong Buy with a $241.69 12-month target.

Danaher to Present at Bank of America Securities Healthcare Conferencestocktitan.netDanaher Shareholders Back Directors, Pay Plan and Auditortipranks.comAssessing Danaher (DHR) Valuation After A Steep Share Price Pullbacksimplywall.st

No material news in the last 48 hours.

Masimo shareholders approved Danaher's $9.9 billion acquisition on May 4, 2026, expected to close in the second half of 2026 pending regulatory clearance, combining Masimo's pulse oximetry and patient monitoring with Danaher's diagnostics portfolio. Danaher announced a $0.40 quarterly cash dividend on May 5 and CEO Rainer Blair presented at the Bank of America Healthcare Conference on May 6. Q1 2026 adjusted EPS of $2.06 beat the $1.94 consensus but revenue of $5.95 billion slightly missed the $6 billion estimate. Shares traded $160.93-$166.28 on May 17, hitting a fresh 52-week low near $172 mid-month after analyst downgrades. Bear case: Danaher stock has fallen 24% in 2026, management is guiding for only 3%-6% revenue growth and EPS of $8.35-$8.50, reflecting a measured recovery; bioprocessing demand recovery remains slower than expected.

Danaher Corp. Stock: Analyst Downgrades and 52-Week Low Testad-hoc-news.deDanaher Stock Fell 24% in 2026 but the EBITDA Data Tells a Different Storytikr.comSolid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen's Large-Cap Stock Picksfinance.yahoo.com

Danaher's $9.9 billion acquisition of Masimo, a pulse oximetry and patient monitoring devices maker, was approved by Masimo shareholders on May 4, 2026, marking a pivotal step toward closing the deal. CEO Rainer Blair presented at the Bank of America Securities Health Care Conference on May 13. The company also declared a regular quarterly cash dividend of $0.40/share. Shares have traded near a 52-week low around $172 after mixed Q1 results (EPS $2.06 beat, revenue $5.95B missed). The Masimo deal expands Danaher's life sciences and diagnostics franchise but carries integration and financing risk via a €3.0B notes issuance.

Danaher Press Releasesinvestors.danaher.comDanaher Corp 52-week low after mixed Q1 resultsad-hoc-news.deDanaher CEO to speak at BofA health care conferencestocktitan.net

On May 13, 2026, Danaher President and CEO Rainer M. Blair presented at the Bank of America Securities Healthcare Conference in Las Vegas at 11:20 a.m. PT, with shares trading near a 52-week low around $172. Q1 2026 results showed adjusted EPS of $2.06 beating $1.94 consensus while revenue of $5.95 billion narrowly missed the $5.99 billion forecast, prompting the company to raise full-year EPS guidance to $8.35-$8.55. Wolfe Research recently lowered its price target to $230 from $260 (Outperform) and Morgan Stanley cut its target to $255 from $270 (Overweight). The pending $9.9 billion Masimo acquisition received Masimo shareholder approval on May 4 and is expected to close in H2 2026. This matters because the Masimo deal is a major capital allocation event that meaningfully reshapes DHR's medical-device exposure. The risk is that the revenue miss and analyst PT cuts reflect deeper end-market softness in bioprocessing and life sciences.

Danaher CEO to speak at BofA health care conference | DHR Stock Newsstocktitan.netAssessing Danaher (DHR) Valuation As Shares Weaken And Undervaluation Debate Growssimplywall.stDanaher stock: Shares slide as institutional holdings shiftad-hoc-news.de

Danaher CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas on May 13, 2026 at 11:20 a.m. PT, webcast on danaher.com. Q1 2026 results showed adjusted EPS of $2.06 surpassing expectations, though revenue missed at $5.95B. On May 5, 2026, the board approved a regular quarterly cash dividend of $0.40 per share payable July 31, 2026 to holders of record June 26, 2026. According to 14 analysts, DHR has a Buy consensus rating with a 2026 price prediction of $243.36. Analysts remain cautiously optimistic about growth trajectory amid a challenging environment.

Danaher CEO at BofA Healthcare Conferencestocktitan.netDanaher Quarterly Dividend May 5investors.danaher.comDanaher Life Sciences Portfolio Focusfinance.yahoo.com

CEO Rainer Blair is scheduled to present at the BofA Securities Healthcare Conference on May 13, an event likely to address recent investor concerns. Shares recently hit a 52-week low near $172 amid mixed Q1 2026 results (adjusted EPS of $2.06 beat, revenue of $5.95-6.0 billion missed) and analyst price-target cuts. The pending $9.9 billion Masimo acquisition was approved by Masimo shareholders on May 4. Danaher also declared a $0.40 quarterly dividend on May 5, payable July 31 to holders of record June 26. Despite the pullback, the analyst consensus remains Buy.

Danaher to Present at BofA Healthcare Conferencestocktitan.netDanaher Announces Quarterly Dividendinvestors.danaher.comDanaher Stock: Analyst Downgrades and 52-Week Low Testad-hoc-news.de